ClinicalTrials.gg
CompletedNCT05757531Updated Jul 5, 2023

A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male Participants

A Phase 1 interventional study of [¹⁴C]-LY3437943 in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-05.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Jun 2023, 3 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
7
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The main purpose of this study is to is to look at how much LY3437943 gets into the bloodstream and how long the body takes to get rid of it in healthy male participants. This study will involve a single dose of 14C radiolabeled LY3437943. his means that a radioactive tracer substance, C14, will be incorporated into the study drug to investigate the study drug and its breakdown products and to find out how much of these pass from blood into urine, feces and expired air.

The study will last up to approximately 15 weeks including the screening period of 28 days.

02

Conditions studied

  • Healthy

Keywords

  • Radioactive
  • ADME
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male participants who are overtly healthy as determined by medical evaluation
  • Have a within the range 18.5 to 32.0 kilograms per meter squared (kg/m²)
  • Have clinical laboratory test results within normal reference range for the population or investigative site, or results outside the normal reference range that are judged to be not by the investigator. Participants with dyslipidemia may be included in the study, at the discretion of the investigator, as long as they fulfill other eligibility criteria
  • Have venous access sufficient to allow for blood sampling as per the protocol
  • Are willing to receive study treatment by SC injections
  • Have a history of a minimum of 1 bowel movement per day
  • use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion criteria

Exclusion Criteria:

  • Have a abnormal blood pressure and/or pulse rate as determined by the investigator at screening or check-in
  • Have significant history of or current cardiovascular, respiratory, hepatic, renal, GI, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the IP; or of interfering with the interpretation of data
  • Have evidence of significant active neuropsychiatric disease, as determined by the investigator
  • Show evidence of infection and/or positive HIV antibodies, and/or positive hepatitis C antibody, and/or positive hepatitis B surface antigen
  • Have a history of constipation or have had acute constipation within 3 weeks prior to check-in
  • Have evidence of active renal disease (eg, diabetic renal disease, polycystic kidney disease) or an estimated of less than 70 mL/minute, calculated using the Chronic Kidney Disease-Epidemiology equation
  • Have a history or presence of pancreatitis (history of chronic pancreatitis or idiopathic acute pancreatitis) and/or elevation in serum amylase or lipase (greater than 1.5-fold the ) at screening
  • Have used or plan to use over-the-counter or prescription medication, and/or dietary or herbal supplements (with the exception of vitamin supplements, acetaminophen and/or thyroid replacement therapy) within 14 days or 5 half-lives (whichever is longer) prior to dosing and for the duration of the study, including any medications that reduce GI motility, including, but not limited to, anticholinergics, antispasmodics, 5 hydroxytryptamine-3 receptor antagonists, dopamine antagonists, and opiates
  • Have had exposure to significant radiation within 12 months prior to dosing (eg, serial x-ray or CT scans, barium meal, being employed in a job requiring radiation exposure monitoring)
  • Have participated in any clinical trial involving a radiolabeled substance within the past 12 months
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    [¹⁴C]-LY3437943

    Single dose of \[¹⁴C\]-LY3437943 administered subcutaneously (SC).

    Drug: [¹⁴C]-LY3437943

Interventions

06

What researchers measure

Primary outcomes

  1. Urinary Excretion of LY3437943 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered

    Urinary Excretion of LY3437943 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered

    Time frame: Predose up to 63 days post dose

  2. Fecal Excretion of LY3437943 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered

    Fecal Excretion of LY3437943 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered

    Time frame: Predose up to 63 days post dose

Secondary outcomes

  1. PK: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC (0-∞)) of Total Radioactivity and [¹⁴C]-LY3437943

    PK: AUC (0-∞) of Total Radioactivity and \[¹⁴C\]-LY3437943

    Time frame: Predose up to 63 days post dose

  2. PK: Maximum Concentration (Cmax) of Total Radioactivity and [¹⁴C]-LY3437943

    PK: Cmax of Total Radioactivity and \[¹⁴C\]-LY3437943

    Time frame: Predose up to 63 days post dose

  3. Total Radioactivity Recovered in Urine, Feces, and Expired Air (if applicable)

    Total Radioactivity Recovered in Urine, Feces, and Expired Air (if applicable)

    Time frame: Predose up to 63 days post dose

  4. Total Number of Metabolites of LY3437943

    Total Number of Metabolites of LY3437943

    Time frame: Predose up to 63 days post dose

07

Study locations

1 site
  • Covance Clinical Research Unit
    Madison, Wisconsin 53704, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2023 to primary completion in Jun 2023, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2023
First posted
Mar 7, 2023
StartActual
Mar 17, 2023
Primary completionActual
Jun 23, 2023
CompletionActual
Jun 23, 2023
Last update
Jul 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05757531
Responsible party
Sponsor
First posted
Mar 7, 2023
Start date
Mar 17, 2023
Primary completion
Jun 23, 2023
Completion
Jun 23, 2023
Last update
Jul 5, 2023

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Retatrutide

Start the discussion